Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

The purpose of this research study is to find out what effects (good and bad) omeprazole and cabazitaxel, or omeprazole and docetaxel, has on participants and their condition. Investigators believe omeprazole may help the other medications work.

Trial Details

NCT ID
NCT04337580
Phase
PHASE2
Sponsor
Wake Forest University Health Sciences
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Omeprazole 80 mg twice daily
Locations (sample)
  • Salisbury, North Carolina, United States|35.67097,-80.47423
  • Winston-Salem, North Carolina, United States|36.09986,-80.24422

Key Eligibility Criteria

  • Patients must have castrate refractory prostate cancer with prior docetaxel treatment which was used in the castrate refractory setting
  • Cancer Progression as defined by prostate cancer working group 3 (PCWG3) any type- prostate specific antigen only, bone only +nodal, nodal only or …
  • Age 18 or older.
  • ECOG 0, 1, or 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →